EYEPOINT PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Anthony P. Adamis, M.D.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Anthony P. Adamis, M.D.”): 44,036,082 for, 370,310 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,022,620 for, 16 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: David Guyer, M.D.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David Guyer, M.D.”): 43,708,357 for, 698,035 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,970,888 for, 51,748 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

The 50 asset managers below reported 9,484,494 for, 525,178 withheld, 12,964 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Jay S. Duker, M.D.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay S. Duker, M.D.”): 44,076,361 for, 330,031 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,022,636 for.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: John B. Landis, Ph.D.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John B. Landis, Ph.D.”): 43,086,644 for, 1,319,748 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,757,711 for, 264,925 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Karen Zaderej

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Karen Zaderej”): 44,034,115 for, 372,277 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,022,620 for, 16 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Nancy Lurker

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nancy Lurker”): 43,072,470 for, 1,333,922 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,754,786 for, 267,850 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Stuart Duty

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stuart Duty”): 44,065,948 for, 340,444 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 10,022,636 for.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Wendy DiCicco

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendy F. DiCicco”): 43,721,247 for, 685,145 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 9,970,888 for, 51,748 withheld.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“3. Amendment to 2019 Employee Stock Purchase Plan”): 44,053,886 for, 205,116 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Amendment to 2019 Employee Stock Purchase Plan The Company's stockholders approved the Second 2019 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 250,000 shares.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 10,024,186 for.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to (i) increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“2. Amendment to 2023 Long-Term Incentive Plan”): 28,353,747 for, 15,905,586 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to (i) increase the number of shares of Common Stock authorized for issuance thereunder by 4,000,000 shares and (ii) increase the individual non-employee director compensation limit contained ther…”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 6,388,661 for, 3,635,895 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“4. Non-Binding Advisory Vote on Named Executive Officer Compensation”): 42,513,914 for, 1,715,072 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 50 managers: 10,012,157 for, 10,479 against. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the company's reported shares outstanding. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

EYEPOINT PHARMACEUTICALS INC.’s own tally for this item (“5. Ratification of Appointment of Independent Registered Public Accounting Firm”): 46,085,482 for, 176,590 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 10,024,002 for, 34 against.

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.